ICON Public FY2024 EPS Estimate Lifted by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for ICON Public in a report issued on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings per share of $13.40 for the year, up from their previous estimate of $13.25. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. ICON Public’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $3.10 earnings per share.

ICLR has been the subject of a number of other reports. Evercore ISI decreased their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. JPMorgan Chase & Co. dropped their target price on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Citigroup reduced their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, Robert W. Baird lowered their price target on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Down 0.4 %

Shares of NASDAQ ICLR opened at $199.47 on Thursday. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The firm has a market capitalization of $16.46 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.54 and a beta of 1.20. The stock has a 50 day moving average price of $210.79 and a 200 day moving average price of $270.01. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

Institutional Trading of ICON Public

Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its position in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in ICON Public by 39.2% in the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 151 shares in the last quarter. Finally, Steph & Co. raised its position in shares of ICON Public by 3.7% in the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 55 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.